Regencell Bioscience Holdings Limited cash flow to debt ratio of -571.91% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Regencell Bioscience Holdings Limited's free cash flow has increased -18.49% from $-4.01M last year to $-3.27M, signaling increasing performance

Regencell Bioscience Holdings Limited's debt to equity ratio is 0.32, which means that the company's assets are healthy financed, signaling financial stability.

Regencell Bioscience Holdings Limited's debt has increased relative to shareholder equity from 0.01 last year to 0.32 today, signaling weakened financials

Regencell Bioscience Holdings Limited has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Regencell Bioscience Holdings Limited's latest filing, so interest coverage cannot be calculated.

Regencell Bioscience Holdings Limited has insufficient data to evaluate this check.

Regencell Bioscience Holdings Limited's short-term assets of $4.90M exceed its short-term liabilities of $663.67K

Regencell Bioscience Holdings Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Regencell Bioscience Holdings Limited's return on equity of -231.87%, is lower than 15.00%, indicating bad performance

Regencell Bioscience Holdings Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Regencell Bioscience Holdings Limited had positive net income in only 0 out of 5 years, indicating unstable earnings

Regencell Bioscience Holdings Limited has negative free cash flow, indicating the company is burning cash rather than generating it

Regencell Bioscience Holdings Limited has negative free cash flow, indicating cash burn

Regencell Bioscience Holdings Limited's yearly earnings has increased -16.68% since last year from $-4.30M to $-3.58M, signaling increasing performance

Regencell Bioscience Holdings Limited's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -444.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Regencell Bioscience Holdings Limited has insufficient revenue history to calculate 3-year revenue CAGR.

Regencell Bioscience Holdings Limited had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Regencell Bioscience Holdings Limited had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Regencell Bioscience Holdings Limited has insufficient data to evaluate this check.

Regencell Bioscience Holdings Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Regencell Bioscience Holdings Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Regencell Bioscience Holdings Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Regencell Bioscience Holdings Limited has insufficient data to evaluate this check.

Regencell Bioscience Holdings Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Regencell Bioscience Holdings Limited has negative shareholder equity; price-to-book is not meaningful and the check fails

Regencell Bioscience Holdings Limited has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue